ADCY6 and breast carcinoma: Our research demonstrates that TET1 is expressed at low levels in breast cancer, leading to the low demethylation of ADCY6, inhibiting ADCY6 protein expression, and regulating the malignant biological behaviour of breast cancer through EMT signalling pathway.